TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11070752

Group type: EXPERIMENTAL
Intervention: Moclobemide (maximum dose 600 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amitriptyline (maximum dose 150 mg per day)
Number of subjects: 60
Study: 8968702

Group type: EXPERIMENTAL
Intervention: Fermented milk product (200 ml daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (200 ml daily)
Number of subjects: 87
Study: 1621746

Group type: EXPERIMENTAL
Intervention: Loracarbef (400 mg twice daily)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500 mg three times daily)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Amoxicillin (500 mg three times daily)
Number of subjects: 390
Study: 6434883

Group type: EXPERIMENTAL
Intervention: Thio-TEPA
Number of subjects: 46

Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 46
Study: 30961463

Group type: EXPERIMENTAL
Intervention: Alteplase (ENCHANTED trial)
Number of subjects: 770
Study: 30057103

Group type: EXPERIMENTAL
Intervention: Tissue adhesive with polyurethane dressing
Number of subjects: 1807

Group type: EXPERIMENTAL
Intervention: Bordered polyurethane dressing
Number of subjects: 1807

Group type: EXPERIMENTAL
Intervention: Securement device with polyurethane dressing
Number of subjects: 1807

Group type: COMPARATOR
Intervention: Polyurethane dressing (control)
Number of subjects: 1807
Study: 26847486

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus resin composite restoration (CTG+RC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CTG
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CTG+RC
Number of subjects: 36
Study: 24454970

Group type: EXPERIMENTAL
Intervention: Multiple doses of AmBisome (7 times 3 mg/kg on days 1-5, 14, and 21)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Single dose of AmBisome 7.5 mg/kg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Single dose of AmBisome 10 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Multiple doses of AmBisome
Number of subjects: 124
Study: 21733953

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg)
Number of subjects: 30
Study: 19781124

Group type: EXPERIMENTAL
Intervention: Nutrition intervention activities focused on lifestyle modification to decrease dietary Na intake; Duration: 10 weeks; Supervised by a registered dietitian.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sub-sample with urine volume of >or=1000 ml; Baseline to 12 months.
Number of subjects: 0
Study: 18058622

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (1000 IU per orally five days per week for 10 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 44
Study: 16219099

Group type: EXPERIMENTAL
Intervention: Implementation of pre-hospital emergency pathway (training module and administration of the guideline)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Current practice (no intervention)
Number of subjects: 750
Study: 17628384

Group type: EXPERIMENTAL
Intervention: 500 mg metformin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 5 mg glyburide
Number of subjects: 28
Study: 10794196

Group type: EXPERIMENTAL
Intervention: Disease management program focusing on self-regulation skills and physical activity
Number of subjects: 570

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570
Study: 8797306

Group type: EXPERIMENTAL
Intervention: PCR‐MWP system for detecting Helicobacter pylori DNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nested‐PCR system (commercial reference laboratory)
Number of subjects: 0
Study: 1293975

Group type: EXPERIMENTAL
Intervention: Flunarizine (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6147121

Group type: EXPERIMENTAL
Intervention: Betaxolol with glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol with glucagon
Number of subjects: 0
Study: 29252113

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) treatment with lymphatic correction plus muscle facilitation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham KT
Number of subjects: 26
Study: 30248217

Group type: EXPERIMENTAL
Intervention: N9-GP 40 IU/kg once-weekly prophylaxis
Number of subjects: 115
Study: 26867076

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Home‐based exercise
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sertraline therapy (50-200 mg daily)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 202
Study: 24582532

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 23508

Group type: COMPARATOR
Intervention: Usual-dose statin (atorvastatin 10 mg, simvastatin 20 to 40 mg, or placebo)
Number of subjects: 23508

Group type: COMPARATOR
Intervention: High-dose versus usual-dose statin or placebo
Number of subjects: 23508

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 23508

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 23508

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist use
Number of subjects: 23508

Group type: EXPERIMENTAL
Intervention: Previous statin use
Number of subjects: 23508
Study: 22414277

Group type: EXPERIMENTAL
Intervention: Citalopram (60 mg/day) with quetiapine (300-450 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Citalopram (60 mg/day) with placebo
Number of subjects: 64
Study: 20456735

Group type: EXPERIMENTAL
Intervention: Microdose (100 microg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Therapeutic dose (60 mg)
Number of subjects: 8
Study: 18515514

Group type: EXPERIMENTAL
Intervention: Membrane sweep
Number of subjects: 300

Group type: COMPARATOR
Intervention: No sweep (control)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Membrane sweep (with cervix > 1 cm dilated)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No sweep (with cervix > 1 cm dilated)
Number of subjects: 300
Study: 15839185

Group type: EXPERIMENTAL
Intervention: Case management by a clinical pharmacist
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 12430368

Group type: EXPERIMENTAL
Intervention: Promogran
Number of subjects: 73

Group type: COMPARATOR
Intervention: Adaptic (Control)
Number of subjects: 73
Study: 10512386

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Scaling with adjunctive antimicrobial therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups received supportive periodontal therapy at 3, 6, 9, 12, 18, and 24 months
Number of subjects: 20
Study: 7856987

Group type: EXPERIMENTAL
Intervention: Zidovudine resistance
Number of subjects: 187

Group type: COMPARATOR
Intervention: Didanosine
Number of subjects: 187
Study: 31194965

Group type: EXPERIMENTAL
Intervention: Ritonavir-containing antiretroviral regimens
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-ritonavir-containing regimens or no antiretrovirals
Number of subjects: 15
Study: 29352831

Group type: EXPERIMENTAL
Intervention: Danish Food-Based Dietary Guidelines (FBDG) adherence indicated by Dietary Quality Index (DQI)
Number of subjects: 219
Study: 27585415

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg intranasal midazolam (INM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intranasal midazolam (INM)
Number of subjects: 118
Study: 24662619

Group type: EXPERIMENTAL
Intervention: Undercarboxylated osteocalcin (ucOC%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total osteocalcin (tOC)
Number of subjects: 0
Study: 22237121

Group type: EXPERIMENTAL
Intervention: Feiji Decoction for soothing the liver combined with psychotherapy and chemotherapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 118
Study: 19560290

Group type: EXPERIMENTAL
Intervention: Modafinil 200mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 16810542

Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood reinfusion system (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard suction drains with homologous banked blood transfusion (group B)
Number of subjects: 60
Study: 15192274

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha‐2b
Number of subjects: 49
Study: 11825635

Group type: EXPERIMENTAL
Intervention: Consumption of fruits
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Consumption of vegetables
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Consumption of soft drinks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Consumption of high-fat-containing snacks
Number of subjects: 40
Study: 9832107

Group type: EXPERIMENTAL
Intervention: >1 mg nicotine (group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: <1 mg nicotine (group 2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (mimicked smoking without a cigarette)
Number of subjects: 21
Study: 7857162

Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate in combination with cefotaxime
Number of subjects: 0
Study: 2683548

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Etidocaine 1.5%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All three local anaesthetics
Number of subjects: 3
Study: 782679

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA), 50 mug four times daily in each nostril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 30
Study: 31558549

Group type: EXPERIMENTAL
Intervention: Biomarker screening and genetic testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarker screening and genetic testing with cascade genetic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27904911

Group type: EXPERIMENTAL
Intervention: Bihemispheric anodal tDCS with conventional swallowing therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 26
Study: 26003889

Group type: EXPERIMENTAL
Intervention: Vildagliptin add-on (50 mg twice a day)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Sulfonylurea dose-increasing by 50%
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Vildagliptin add-on
Number of subjects: 344

Group type: COMPARATOR
Intervention: Sulfonylurea dose-increasing
Number of subjects: 344
Study: 23755215

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals (ALLRT cohort)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-uninfected persons (NHANES cohort)
Number of subjects: 0
Study: 21795635

Group type: COMPARATOR
Intervention: Combined bolus infusion of GH or saline and continuous stimulation by saline GH‐releasing hormone (GHRH), GHRP‐2, or both peptides after randomly ordered supplementation with placebo vs. E(2) (estrogen; women) and T (testosterone; men)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Peptidyl secretagog
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IGF‐I
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 25
Study: 19698059

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 756

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 756
Study: 16936418

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intracoronary administration of nicorandil (Group B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No nicorandil administration (Group C)
Number of subjects: 92
Study: 14614600

Group type: EXPERIMENTAL
Intervention: lansoprazole
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ecabet sodium
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: rebamipide
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: nizatidine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: polaprezinc
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: teprenone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: cetraxate hydrochloride
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 64
Study: 10732535

Group type: EXPERIMENTAL
Intervention: 8-week home-based exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 0
Study: 8618155

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Voluntary contraction
Number of subjects: 40
Study: 1399930

Group type: EXPERIMENTAL
Intervention: Aztreonam/vancomycin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Piperacillin/gentamicin
Number of subjects: 36
Study: 4044346

Group type: EXPERIMENTAL
Intervention: High dose per fraction radiotherapy at 9 Gy X 3
Number of subjects: 14

Group type: COMPARATOR
Intervention: High dose per fraction radiotherapy at 5 Gy X 8 twice weekly
Number of subjects: 14
Study: 30099973

Group type: EXPERIMENTAL
Intervention: Volunteer intervention (1:1 person‐centered care with a focus on nutrition and hydration support, hearing and visual aids, activities, and orientation)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Control group (patients admitted 12 months prior to the volunteer program)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Volunteer intervention
Number of subjects: 458
Study: 27871505

Group type: EXPERIMENTAL
Intervention: Sugammadex (2-4 mg · kg‐1) after deep neuromuscular block with 0.6 mg · kg‐1 rocuronium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neostigmine (50 μg · kg‐1) after shallow neuromuscular block with 0.45 mg · kg‐1 rocuronium
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sugammadex (2-4 mg · kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neostigmine (50 μg · kg‐1)
Number of subjects: 100
Study: 25189164

Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 377
Study: 22820319

Group type: EXPERIMENTAL
Intervention: Palivizumab (one-monthly intramuscular injections during RSV season, minimum of 2 injections)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (one-monthly intramuscular injections during RSV season, minimum of 2 injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palivizumab and Placebo
Number of subjects: 0
Study: 20444625

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1809
Study: 18827610

Group type: EXPERIMENTAL
Intervention: Oral topotecan (OT) with best supportive care
Number of subjects: 141

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 141
Study: 16376650

Group type: EXPERIMENTAL
Intervention: Foldable silicone, sharp optic edge IOL
Number of subjects: 53

Group type: COMPARATOR
Intervention: Silicone, rounded optic edge IOL
Number of subjects: 53

Group type: COMPARATOR
Intervention: Acrylate, sharp optic edge IOL
Number of subjects: 53
Study: 11954700

Group type: EXPERIMENTAL
Intervention: PCA + fuzzy logic control (FLC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional PCA
Number of subjects: 25
Study: 9542558

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms.kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 7534966

Group type: EXPERIMENTAL
Intervention: fetal fibronectin (fFN)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: alpha-fetoprotein (AFP)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: diamino-oxydase (DAO)
Number of subjects: 131
Study: 2198072

Group type: EXPERIMENTAL
Intervention: Exploratory therapy (relationship-oriented)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prescriptive therapy (cognitive/behavioural)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Eight sessions of therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 16 sessions of therapy
Number of subjects: 120
Study: 387000

Group type: EXPERIMENTAL
Intervention: DL-phenylalanine (150-200 mg/24 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Imipramine (150-200 mg/24 h)
Number of subjects: 40
Study: 31870394

Group type: EXPERIMENTAL
Intervention: Community-based preventive intervention including screening for hypertension, diabetes, and stroke, followed by referral to a mobile outreach clinic, guideline-based treatment, monthly home visits by CHWs for medication compliance, and counseling on reducing salt consumption and quitting tobacco and alcohol.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) arm providing information on the ill effects of tobacco use and steps to quit, with access to the government's national programme for the prevention and control of non-communicable diseases.
Number of subjects: 32
Study: 28952325

Group type: EXPERIMENTAL
Intervention: Text message intervention for 9 months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study: 28492194

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) mouth rinse
Number of subjects: 75

Group type: COMPARATOR
Intervention: Combination mouth rinse (chlorhexidine and sodium fluoride)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Green tea extract (0.5%) mouth rinse
Number of subjects: 75
Study: 25673557

Group type: EXPERIMENTAL
Intervention: Milk (500 ml) - Female
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Milk (500 ml) - Male
Number of subjects: 32

Group type: COMPARATOR
Intervention: Carbohydrate (500 ml) - Female
Number of subjects: 32

Group type: COMPARATOR
Intervention: Carbohydrate (500 ml) - Male
Number of subjects: 32
Study: 23098696

Group type: EXPERIMENTAL
Intervention: Swedish massage
Number of subjects: 54

Group type: COMPARATOR
Intervention: Touch (control group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study: 20415916

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium hydroxide (Ca(OH)(2)) lining cement
Number of subjects: 0
Study: 19317162

Group type: EXPERIMENTAL
Intervention: Ziyin Tongbi Decoction (ZTD), one dose per day, consisting of various herbal ingredients, taken twice daily (150 mL each time) for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Longbishu Capsule, 0.9 g each time, taken twice a day for 4 weeks
Number of subjects: 100
Study: 16365065

Group type: EXPERIMENTAL
Intervention: Fish oil (5 mL daily for 3 months)
Number of subjects: 83
Study: 12573743

Group type: EXPERIMENTAL
Intervention: Altered fractionation in radiotherapy (EORTC 22851 and CHART trials)
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Conventional fractionation in radiotherapy (EORTC 22851 and CHART trials)
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Hyperfractionation in radiotherapy (PMH trial)
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Conventional fractionation in radiotherapy (PMH trial)
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Compliance to prescribed radiation therapy schedule
Number of subjects: 2566

Group type: EXPERIMENTAL
Intervention: Recent treatment compliance
Number of subjects: 2566
Study: 11132811

Group type: EXPERIMENTAL
Intervention: AIM-dyad condition
Number of subjects: 108

Group type: COMPARATOR
Intervention: Individual control training condition
Number of subjects: 108
Study: 9372795

Group type: EXPERIMENTAL
Intervention: NaF toothpaste containing 1500 ppm fluoride
Number of subjects: 4196

Group type: COMPARATOR
Intervention: NaF toothpaste containing 1000 ppm fluoride
Number of subjects: 4196

Group type: EXPERIMENTAL
Intervention: NaF toothpaste with trimetaphosphate (TMP)
Number of subjects: 4196

Group type: EXPERIMENTAL
Intervention: Subjects brushing more frequently
Number of subjects: 4196

Group type: EXPERIMENTAL
Intervention: Subjects not using a tumbler to rinse after toothbrushing
Number of subjects: 4196
Study: 10126852

Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' consultations
Number of subjects: 236
Study: 2861311

Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide + triamterene)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 840
Study: 30456564

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU/week)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 30369600

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study: 26652811

Group type: EXPERIMENTAL
Intervention: Nasoduodenal (ND) feeding
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasogastric (NG) feeding
Number of subjects: 40
Study: 25034003

Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglicate cutaneous emulsion
Number of subjects: 208

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 208
Study: 22930120

Group type: COMPARATOR
Intervention: No past year alcohol use (AUDIT‐C 0)
Number of subjects: 3930

Group type: EXPERIMENTAL
Intervention: Low-level alcohol use (AUDIT‐C 1-3)
Number of subjects: 3930

Group type: EXPERIMENTAL
Intervention: Mild alcohol misuse (AUDIT‐C 4-5)
Number of subjects: 3930

Group type: EXPERIMENTAL
Intervention: Moderate alcohol misuse (AUDIT‐C 6-7)
Number of subjects: 3930

Group type: EXPERIMENTAL
Intervention: Severe alcohol misuse (AUDIT‐C 8-12)
Number of subjects: 3930
Study: 21054297

Group type: EXPERIMENTAL
Intervention: Environmental barriers (lack of resting places, long distances, noisy traffic, dangerous crossroads, hilly terrain, poor street condition)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Fear of moving outdoors
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Unmet physical activity need
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Slower walking speed
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: More chronic diseases
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Environmental barriers, fear of moving outdoors, unmet physical activity need
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Distances
Number of subjects: 589